Nevro Spine-Stim Patents Escape Re-Review By PTO
This article was originally published in The Gray Sheet
Executive Summary
The Patent Trial and Appeals Board won’t review a Nevro spinal cord stimulator patent after a challenge from Boston Scientific claimed the patent was invalid because it was too similar to prior knowledge in the field. The unusual decision not to even launch a so-called inter partes review in this case should be comforting to device patent holders, an attorney says.
You may also be interested in...
Nevro Will Take On Spinal Cord Stim Leaders As Senza Is Stamped 'Superior'
The company says the Senza high-frequency system is the first spinal cord stimulator to be approved to claim superiority over existing spinal cord stimulation therapies. Approval is based on results of the highly touted SENZA-RCT trial.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.